Novel routes for allergen immunotherapy: Safety, efficacy and mode of action

Immunotherapy

Volumn 4, Issue 2, 2012, Pages 201-212

  Moingeon, Philippe ^a   Mascarell, Laurent ^a  

^a Stallergenes SA   (France)

Author keywords

allergen; APC; immunotherapy; mucosal immunity; regulatory T lymphocyte

Indexed keywords

PLACEBO; POLLEN ANTIGEN;

ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; EPICUTANEOUS ALLERGEN SPECIFIC IMMUNOTHERAPY; FOOD ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INTERMETHOD COMPARISON; INTRALYMPHATIC ALLERGEN SPECIFIC IMMUNOTHERAPY; INTRANASAL ALLERGEN SPECIFIC IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; PATIENT SAFETY; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; THERAPY EFFECT; THROAT IRRITATION; TONGUE SWELLING;

ALLERGENS; ANAPHYLAXIS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; HUMANS; HYPERSENSITIVITY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84857523576     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.171     Document Type: Review

References (148)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 2, 1572-1573 (1911).
2. Canonica G, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 64, 1-59 (2009).
3. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118, 434-440 (2006).
4. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120, 1338-1345 (2007).
5. Ibanez MD, Kaiser F, Knecht R et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr. Allergy Immunol. 18, 516-522 (2007).
6. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol. 121, 512-518 (2008).
7. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 123, 160-166 (2009).
8. Didier A, Melac M, Montagut A et al. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 64, 166-171 (2009).
9. Horak F, Jaeger S, Worm M, Melac M, Didier A. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin. Exp. Allergy 39, 394-400 (2009).
10. Malling HJ, Montagut A, Melac M et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin. Exp. Allergy 39, 387-393 (2009).
11. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102, 558-562 (1998).
12. Larche M. Specific immunotherapy. Br. Med. Bull. 56, 1019-1036 (2000).
13. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: The ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin. Exp. Allergy 29, 497-506 (1999).
14. Michils A, Mairesse M, Ledent C et al. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: Conversion with immunotherapy and relation to subclass expression. J. Allergy Clin. Immunol. 102, 118-126 (1998).
15. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: Significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56, 301-306 (2001).
16. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109, 251-256 (2002).
17. Powell RJ, Frew AJ, Corrigan CJ, Durham SR. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 62, 1335-1338 (2007).
18. Maloy KJ, Erdmann I, Basch V et al. Intralymphatic immunization enhances DNA vaccination. Proc. Natl Acad. Sci. USA 98, 3299-3303 (2001).
19. Johansen P, Haffner AC, Koch F et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur. J. Immunol. 35, 568-574 (2005).
20. von Beust BR, Johansen P, Smith KA et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur. J. Immunol. 35, 1869-1876 (2005).
21. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr. Opin Allergy Clin. Immunol. 9, 537-543 (2009).
22. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc. Natl Acad. Sci. USA 105, 17908-17912 (2008).
23. Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. La Presse Medicale 67, 2299-2301 (1959).
24. Werfel T. Epicutaneous allergen administration: A novel approach for allergen-specific immunotherapy? J. Allergy Clin. Immunol. 124, 1003-1004 (2009).
25. Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: Is this the future of allergen-specific immunotherapy? Allergy 66, 798-809 (2011).
26. Senti G, Graf N, Haug S et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 124, 997-1002 (2009).
27. Dupont C, Kalach N, Soulaines P et al. Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity. J. Allergy Clin. Immunol. 125, 1165-1167 (2010).
28. Deuschl H, Johansson GO. Hyposensitization of patients with allergic rhinitis by intranasal administration of chemically modified grass pollen allergen. A pilot study. Acta Allergol. 32, 248-262 (1977).
29. Nickelsen JA, Goldstein S, Mueller U et al. Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response. J. Allergy Clin. Immunol. 68, 33-40 (1981).
30. Georgitis JW, Reisman RE, Clayton WF et al. Local intranasal immunotherapy for grass-allergic rhinitis. J. Allergy Clin. Immunol. 71, 71-76 (1983).
31. Nickelsen JA, Georgitis JW, Mueller UR et al. Local nasal immunotherapy for ragweed-allergic rhinitis. III. A second year of treatment. Clin. Exp. Allergy 13, 509-519 (1983).
32. Andri L, Senna GE, Betteli C et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 47, 318-323 (1992).
33. Andri L, Senna G, Betteli C et al. Local nasal immunotherapy for Dermatophagoides-induced rhinitis: Efficacy of a powder extract. J. Allergy Clin. Immunol. 91, 987-996 (1993).
34. D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin. Exp. Allergy 25, 141-148 (1995).
35. Andri L, Senna G. Local nasal immunotherapy. Allergy 50, 190 (1995).
36. Andri L, Senna G, Betteli C et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: A double-blind study. J. Allergy Clin. Immunol. 97, 34-41 (1996).
37. Bellussi L, Bologna M, Di Stanislao C et al. Simplified local nasal immunotherapy in mite dust allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 12, 42-47 (2002).
38. Tsai JJ, Liao EC, Tsai FH, Hsieh CC, Lee MF. The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus. J. Asthma 46, 165-170 (2009).
39. Passalacqua G, Albano M, Riccio AM, Scordamaglia A, Canonica GW. Local nasal immunotherapy: Experimental evidences and general considerations. Allergy 52, 10-16 (1997).
40. Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4-5 years. J. Investig. Allergol. Clin. Immunol. 13, 228-231 (2003).
41. Egger C, Horak F, Vrtala S, Valenta R, Niederberger V. Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses. J. Allergy Clin. Immunol. 126, 1312-1315 (2010).
42. Rebien W, Puttonen E, Maasch HJ, Stix E, Wahn U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur. J. Pediatr. 138, 341-344 (1982).
43. Taudorf E, Weeke B. Orally administered grass pollen. Allergy 38, 561-564 (1983).
44. Mosbech H, Dreborg S, Madsen F et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy 42, 451-455 (1987).
45. Urbanek R, Burgelin KH, Kahle S, Kuhn W, Wahn U. Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur. J. Pediatr. 149, 545-550 (1990).
46. Taudorf E, Laursen LC, Lanner A et al. Oral immunotherapy in birch pollen hay fever. J. Allergy Clin. Immunol. 80, 153-161 (1987).
47. Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 41, 271-279 (1986).
48. Taudorf E, Laursen L, Lanner A et al. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J. Allergy Clin. Immunol. 83, 589-594 (1989).
49. Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Ann. Allergy 64, 27-31 (1990).
50. Litwin A, Flanagan M, Entis G et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: A double-blind study. J. Allergy Clin. Immunol. 100, 30-38 (1997).
51. Giovane AL, Bardare M, Passalacqua G et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: Evidence of safety and efficacy in paediatric patients. Clin. Exp. Allergy 24, 53-59 (1994).
52. Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: Implications for future treatment. J. Allergy Clin. Immunol. 121, 1344-1350 (2008).
53. Buchanan AD, Green TD, Jones SM et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol. 119, 199-205 (2007).
54. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 59, 980-987 (2004).
55. Meglio P, Giampietro PG, Gianni S, Galli E. Oral desensitization in children with immunoglobulin E-mediated cow's milk allergy - follow-up at 4 yr and 8 months. Pediatr. Allergy Immunol. 19, 412-419 (2008).
56. Staden U, Rolinck-Werninghaus C, Brewe F et al. Specific oral tolerance induction in food allergy in children: Efficacy and clinical patterns of reaction. Allergy 62, 1261-1269 (2007).
57. Longo G, Barbi E, Berti I et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J. Allergy Clin. Immunol. 121, 343-347 (2008).
58. Skripak JM, Nash SD, Rowley H et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J. Allergy Clin. Immunol. 122, 1154-1160 (2008).
59. Varshney P, Jones SM, Scurlock AM et al. A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response. J. Allergy Clin. Immunol. 127, 654-660 (2011).
60. Morris DL. Treatment of respiratory disease with ultra-small doses of antigens. Ann. Allergy 28, 494-500 (1970).
61. Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study. Allergy 54, 249-260 (1999).
62. La Rosa M, Ranno C, Andre C et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 104, 425-432 (1999).
63. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2, CD002893 (2003).
64. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53, 493-498 (1998).
65. Vourdas D, Syrigou E, Potamianou P et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53, 662-672 (1998).
66. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108, S147-S334 (2001).
67. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind, placebo-controlled study. Allergy 55, 842-849 (2000).
68. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3?year randomized controlled study. J. Allergy Clin. Immunol. 115, 1184-1188 (2005).
69. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy 60, 4-12 (2005).
70. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol. Clin. Immunol. 15, 9-16 (2005).
71. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: Systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 61, 1162-1172 (2006).
72. Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: A meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 97, 141-148 (2006).
73. Larenas-Linnemann D. Sublingual immunotherapy in children: Complete and updated review supporting evidence of effect. Curr. Opin Allergy Clin. Immunol. 9, 168-176 (2009).
74. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma. Immunol. 93, 3-12(2004).
75. Pajno GB, Peroni DG, Vita D et al. Safety of sublingual immunotherapy in children with asthma. Paediatr. Drugs 5, 777-781 (2003).
76. Mascarell L, Van Overtvelt L, Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol. Allergy Clin. North Am. 26, 283-306 (2006).
77. Baena-Cagnani CE, Passalacqua G, Baena-Cagnani RC, Croce VH, Canonica WG. Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Curr. Opin Allergy Clin. Immunol. 5, 173-177 (2005).
78. Fiocchi A, Pajno G, La Grutta S et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. 95, 254-258 (2005).
79. Didier A, Melac M, Combebias A, Andre C. Efficacy and safety of sublingual immunotherapy grass pollen tablets in grass pollen rhinoconjonctivitis. J. Allergy Clin. Immunol. 117, 721 (2006).
80. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J. Allergy Clin. Immunol. 118, 1292-1298 (2006).
81. Bussmann C, Maintz L, Hart J et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: A pilot study. Clin. Exp. Allergy 37, 1277-1285 (2007).
82. Pajno GB, Caminiti L, Vita D et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 120, 164-170 (2007).
83. Calderon MA, Casale TB, Togias A et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J. Allergy Clin. Immunol. 127, 30-38 (2011).
84. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 126, 466-476 (2010).
85. Mondoulet L, Dioszeghy V, Vanoirbeek JA et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int. Arch. Allergy Immunol. 154, 299-309 (2011).
86. Mondoulet L, Dioszeghy V, Ligouis M et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin. Exp. Allergy 40, 659-667 (2010).
87. 3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61, 173-180 (2006).
88. Mascarell L, Saint-Lu N, Moussu H et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol. 4, 638-647 (2011).
89. Van Overtvelt L, Moussu H, Horiot S et al. Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine. 28, 2986-2992 (2010).
90. Saint-Lu N, Tourdot S, Razafindratsita A et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64, 1003-1013 (2009).
91. Lee SE, Koh YI, Kim MK et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J. Clin. Immunol. 28, 157-165 (2008).
92. Lombardi V, Van Overtvelt L, Horiot S et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy 38, 1819-1829 (2008).
93. Van Overtvelt L, Lombardi V, Razafindratsita A et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int. Arch. Allergy Immunol. 145, 152-162 (2008).
94. Razafindratsita A, Saint-Lu N, Mascarell L et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J. Allergy Clin. Immunol. 120, 278-285 (2007).
95. Hisbergues M, Magi M, Rigaux P et al. In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin. Exp. Allergy. 37, 1286-1295 (2007).
96. Mascarell L, Van Overtvelt L, Lombardi V et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/Treg immune responses and enhances tolerance induction via the sublingual route. Vaccine 26, 108-118 (2007).
97. Liu YH, Tsai JJ. Production of salivary immunoglobulin A and suppression of Dermatophagoides pteronyssinus-induced airway inflammation by local nasal immunotherapy. Int. Arch. Allergy Immunol. 138, 161-168 (2005).
98. Hufnagl K, Focke M, Gruber F et al. Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides. Clin. Exp. Allergy 38, 1192-1202 (2008).
99. Allam JP, Duan Y, Winter J et al. Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. Allergy 66, 532-539 (2011).
100. 4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand. J. Immunol. 64, 251-259 (2006).
101. Sun JB, Czerkinsky C, Holmgren J. Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand. J. Immunol. 66, 278-286 (2007).
102. Daniel C, Repa A, Wild C et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61, 812-819 (2006).
103. Mousavi T, Tajik N, Moradi M, Radjabzadeh MF. CpG immunotherapy in Chenopodium album sensitized mice: The comparison of IFN-gamma, IL-10 and IgE responses in intranasal and subcutaneous administrations. Clin. Mol. Allergy 6, 10 (2008).
104. Liu Z, Guo H, Wu Y et al. Local nasal immunotherapy: Efficacy of Dermatophagoides farinae - chitosan vaccine in murine asthma. Int. Arch. Allergy Immunol. 150, 221-228 (2009).
105. Dioszeghy V, Mondoulet L, Dhelft V et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J. Immunol. 186, 5629-5637 (2011).
106. 4+ T cells. J. Allergy Clin. Immunol. 122, 603-609 (2008).
107. Faria AM, Weiner HL. Oral tolerance: Therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13, 143-157 (2006).
108. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194, 629-644 (2001).
109. 4+CD45RBhigh- induced colitis by a TGF-beta-dependent mechanism. J. Immunol. 170, 2516-2522 (2003).
110. 4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J. Immunol. 180, 7327-7337 (2008).
111. Sun CM, Hall JA, Blank RB et al. Small intestine lamina propria dendritic cells promote de novo generation of FoxP3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775-1785 (2007).
112. Sun JB, Flach CF, Czerkinsky C, Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: Powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol. 181, 8278-8287 (2008).
113. 3+ regulatory T cells in the lamina propria. Immunity 34, 237-246 (2011).
114. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 121, 1120-1125 (2008).
115. Nickelsen JA, Goldstein S, Mueller U et al. Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response. J. Allergy Clin. Immunol. 68, 41-45 (1981).
116. Patriarca G, Nucera E, Roncallo C et al. Oral desensitizing treatment in food allergy: Clinical and immunological results. Aliment. Pharmacol. Ther. 17, 459-465 (2003).
117. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during immunotherapy. Clin. Exp. Allergy 33, 1171-1174 (2003).
118. Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann. Allergy Asthma. Immunol. 84, 241-243 (2000).
119. Iliopoulos O, Proud D, Adkinson NF Jr et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: Changes in inflammatory mediators and cells. J. Allergy Clin. Immunol. 87, 855-866 (1991).
120. Bousquet PJ, Calderon MA, Demoly P et al. The Consolidated Standards of Reporting Trials (CONSORT) statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA(2)LEN) article. J. Allergy Clin. Immunol. 127, 49-56 (2011).
121. 4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163, 2944-2952 (1999).
122. van Neerven RJ, Arvidsson M, Ipsen H et al. A double-blind, placebo-controlled birch allergy vaccination study: Inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin. Exp. Allergy 34, 420-428 (2004).
123. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual FoxP3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy 40, 598-606 (2010).
124. Bahceciler NN, Arikan C, Taylor A et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int. Arch. Allergy Immunol. 136, 287-294 (2005).
125. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. 102, 157-164 (1998).
126. El Biaze M, Boniface S, Koscher V et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 58, 844-853 (2003).
127. Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin. Exp. Allergy 28, 917-920 (1998).
128. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL?12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol. 99, 254-260 (1997).
129. Benjaponpitak S, Oro A, Maguire P et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J. Allergy Clin. Immunol. 103, 468-475 (1999).
130. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27, 1007-1015 (1997).
131. 4+ T cells from allergic individuals. J. Exp. Med. 178, 2123-2130 (1993).
132. Ciprandi G, Morandi F, Olcese R, Silvestri M, Tosca MA. Subcutaneous and sublingual immunotherapy and T regulatory cells: There is clinical relevance. Clin. Exp. Allergy 40, 1578-1579 (2010).
133. Meiler F, Zumkehr J, Klunker S et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205, 2887-2898 (2008).
134. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J. Clin. Invest. 114, 1389-1397 (2004).
135. Piconi S, Trabattoni D, Rainone V et al. Immunological effects of sublingual immunotherapy: Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J. Immunol. 185, 7723-7730 (2010).
136. Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr. Opin Allergy Clin. Immunol. 9, 554-557 (2009).
137. Allam JP, Novak N, Fuchs C et al. Characterization of dendritic cells from human oral mucosa: A new Langerhans' cell type with high constitutive FcepsilonRI expression. J. Allergy Clin. Immunol. 112, 141-148 (2003).
138. Allam JP, Wurtzen PA, Reinartz M et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J. Allergy Clin. Immunol. 126, 638-645 (2010).
139. Allam JP, Peng WM, Appel T et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121, 368-374 (2008).
140. Marcucci F, Sensi L, Incorvaia C et al. Oral reactions to sublingual immunotherapy: A bioptic study. Allergy 62, 1475-1477 (2007).
141. Allam JP, Stojanovski G, Friedrichs N et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 63, 720-727 (2008).
142. 4+ T cells. Clin. Exp. Allergy 39, 1910-1919 (2009).
143. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol. 2, 446-453 (2002).
144. Batard T, Didierlaurent A, Chabre H et al. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int. Arch. Allergy Immunol. 136, 239-249 (2005).
145. Moingeon P, Lombardi V, Saint-Lu N et al. Adjuvants and vector systems for allergy vaccines. Immunol. Allergy Clin. North Am. 31, 407-419 (2011).
146. Senti G, Johansen P, Haug S et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: A Phase I/IIa clinical trial. Clin. Exp. Allergy Immunol. 39, 562-570 (2009).
147. Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: A Phase I/IIa study. Int. Arch. Allergy Immunol. 154, 336-344 (2011).
148. Mascarell L, Zimmer A, Van Overtvelt L, Tourdot S, Moingeon P. Induction of allergen-specific tolerance via mucosal routes. Curr. Top. Microbiol. Immunol. 820, 85-105 (2011).